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The Impact of MITF on Melanoma
Development: News from Bench and
Bedside
Elisabeth M. Roider1 and David E. Fisher1
In the current issue, two articles highlight the impact of melanocyte transcription
factor (MITF) on melanoma development. In the first, Lister et al. reveal in vivo
proof of MITF directly regulating tumor development in BRAFV600E melanomas. In
the second, Sturm et al. present a clinical trial that emphasizes the importance of
the recently discovered E318K MITF germline mutation in patients with multiple
primary melanomas.
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MITF and its role in BRAFV600E
melanoma
The master melanocyte transcription fac-
tor (MITF) is a member of the micro-
phthalmia-related transcription factor
(MiT) family, and it has key roles in
survival, growth, and differentiation of
melanocytes, retinal pigment epithe-
lium, osteoclasts, and other hemato-
poietic lineages (Haq and Fisher, 2011).
Several MiT family members, in addition
to MITF, have been associated with
cancer—specifically TFE3 (in renal
carcinomas and Alveolar Soft Parts Sar-
coma) and TFEB (in renal carcinomas).
Upstream and downstream alterations of
MITF are known to change melanoma
phenotype and function. Both high and
low MITF expression levels have been
associated with melanoma development.
Recently, the complex interactions
among genetic and environmental fac-
tors in melanoma have been a focus of
intense research. About 50% of mela-
noma patients exhibit somatic mutations
in the BRAF gene coding for the
BRaf serine/threonine kinase involved
in the Ras/Raf–mitogen-activated pro-
tein kinase pathway. So far, over 30
different BRAF mutations are known to
exist, although BRAFV600E is by far the
most common mutation. Its discovery
was followed by successful application
of small-molecule inhibitors in clinical
trials (Flaherty et al., 2012), although
drug resistance remains a problem.
Since the discovery of MITF’s oncoge-
nic amplification in human mela-
nomas (Garraway et al., 2005) and
the in vitro studies that corroborated
a potential interplay of BRAF and MITF
(Wellbrock and Marais, 2005), recent
studies have assigned BRAFV600E a
critical role in sustaining MITF activity
at an intermediate level, enabling tumor
growth (Hoek and Goding, 2010).
However, in vivo analyses have thus
far been lacking.
The published work of Lister et al.
(2013) begins to close this gap. A
temperature-sensitive mitfavc7 mutant
allele enables MITF activity to be
varied within an individual animal by
altering water temperature. The mitfavc7
allele is a splice-site mutation at the
intron 6 splice donor site inducing a
reduction in melanocyte numbers
when zebrafish are reared at less
than 26 1C, and an almost complete
loss of melanocytes at a temperature
higher than 28 1C. Lister and co-
workers crossed this mitfavc7 mutant
zebrafish with a transgenic BRAFV600E
fish to generate BRAFV600E/V600E
mitfavc7/vc7 (BRAFV600Emitf) animals.
On comparing BRAFV600Emitf zebrafish
with BRAFV600E/V600Ep53M215K/M215K
(BRAFV600Ep53) fish, BRAFV600Emitf
mutants showed an expression of the
intron 6–mutated mitfa transcript and an
almost complete loss of the mitfa tran-
script. BRAFV600Emitf mutants, when
exposed to low levels of MITF, devel-
oped pigmented lesions; 18 out of 67
lesions progressed to melanomas, a mel-
anoma incidence similar to that found in
BRAFV600Ep53 zebrafish (48/177). Not
surprisingly, in vivo abrogation of MITF
revealed an impressive tumor regression
in 12 out of 15 melanomas after 8 weeks.
Complete tumor regression occurred in 6
of the 12, as indicated by melanophage
infiltration and increased apoptosis in
tumor tissues. However, after increasing
MITF levels, the tumors relapsed at the
previous sites. Taken together, these data
strongly indicate direct interaction
between MITF and growth/survival of
BRAFV600E melanomas, as well as a key
survival role for MITF within BRAFV600E-
driven melanomas.
The E318K mutation in melanoma
So far, relatively few mutations have been
linked to familial melanoma. In addition
to CDKN2A and CDK4, a human germ-
line mutation of MITF has now been
identified. By performing whole-exome
sequencing of patients from several mel-
anoma families, Yokoyama et al. (2011)
identified an individual carrying a
germline variant (coding DNA sequence
c.G1075A; protein sequence p.E318K;
rs149617956) in MITF. Linkage analysis
of 31 families subsequently identified to
carry the variant generated a log of
odds score of 2.7 under a dominant
model, indicating E318K as a possible
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intermediate risk variant. Large-scale scree-
ning of an Australian cohort confirmed the
impact of the E318K variant. Whereas the
MITF E318K variant was found in 14 out of
1,953 controls, it was present in 34 of the
2,059 controls. The MITF E318K variant
was particularly augmented in cases
displaying multiple primary melanomas
and in those with a family history of
melanoma. Consistent with a gain-of-
function state for MITF, the variant was
also reported to be associated with non-
blue eye color. The gain of function
was shown to correspond to loss of a
previously described SUMOylation site at
codon 318 on MITF (Miller et al., 2005),
which is otherwise antagonistic to MITF’s
transcriptional function. Subsequent repli-
cation of these findings in two independent
population-based case–control samples
from the United Kingdom confirmed that
the MITF E318K variant occurred much
more commonly in cases than in controls.
Bertoletto et al. (2011) sequenced the MITF
gene in 62 patients with both melanoma
and renal cell cancer and discovered
the same heterozygous germline mutation
resulting in the substitution of glutamic
acid 318 with lysine (E318K), as well as
similar alterations in MITF SUMOylation
and transcriptional activity. Later, an Italian
study examined 667 melanoma patients,
revealing a 3-fold higher risk for deve-
loping melanoma, and a 6.4-fold higher
risk for developing multiple primary mela-
nomas for MITF E318K carriers compared
with control populations. Furthermore, this
mutation has been associated with an
increased nevus number and non-blue
eye color. In addition, carriers with a per-
sonal and/or family history of pancreatic
cancer and kidney patients seemed to
suffer from a significantly higher risk of
developing melanoma (Ghiorzo et al.,
2013). However, a clear phenotypic
characterization of nevi and tumor pat-
terns in MITF E318K melanoma patients
has been lacking so far.
In the current issue, Sturm et al. (2013)
screened 288 volunteer patients for the
MITF E318K mutation and iden-
tified six carriers. Whereas all of these
patients were fair skinned and had
suffered from multiple primary melano-
mas, none showed a mutation in the
CDK2A locus, and two out of the six
patients were found to be red-haired
MC1R R/R homozygotes. Eye imaging
revealed an almost equal number of
blue and non-blue eye color carriers.
Furthermore, patients carrying the MITF
E318K mutation showed a significantly
higher number (P¼0.008) of nevi larger
than 5mm. Out of the total of 13 mela-
nomas excised from the E318K carriers,
histopathology identified four amelanotic
melanomas. The corresponding incidence
of 30.7% was clearly higher than the
generally reported frequency of 2–8%,
suggesting a possible impact of the MITF
E318K mutation on the development of
amelanotic tumors. As 3 out of these 4
melanomas were obtained from a MITF
E318K carrier patient showing a MC1R
homozygous R/R genotype, suggesting
that interplay of MITF E318K mutants
and MC1R variants might contribute to
the formation of melanomas, especially
amelanotic melanomas. However, further
large-scale studies are needed.
Taken together, these translational stu-
dies highlight the crucial impact of MITF
on melanoma risk and development. In
2010, a phase one study evaluating drug
tolerance of an histone deacetylase inhibi-
tor inhibitor, shown to suppress MITF
expression (Yokoyama et al., 2008), was
initiated (http://www.clinicaltrials.gov, Iden-
tifier: NCT01065467, accessed 10 August
2013). Further identification of MITF
modulating small molecules and a better
understanding of the cellular and molecular
relationship between MC1R variants,
E318K, and BRAF/NRAS mutations will
be necessary to fully understand MITF’s
role(s) in melanoma pathogenesis and to
optimize strategies from bench to bedside.
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Clinical Implications
 Screening for CDKN2A, CDK4, and the recently discovered E318K mutation
should be performed in all patients presenting with a history of familial
melanomas or a history of multiple primary melanomas, because of the
potential ability to identify family members with elevated risk.
With regard to melanoma development, and especially in amelanotic
melanomas, special attention should be paid to MC1R-mutant red-haired
patients bearing the E318K mutation.
 In a zebrafish model, abrogation of MITF activity in BRAFV600E melanomas
revealed complete melanoma regression, highlighting possible therapeutic
opportunities for humans. Further investigation of small-molecule mod-
ulators of MITF may lead to useful methods of treatment.
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